Time toxicity of nivolumab in metastatic head and neck squamous cell carcinoma patients: a single-institution experience
Our study provides an important and underexplored patient-centered metric in TT, especially in the context of incurable HNSCC with abysmal survival outcome. Our findings suggest that TT varies significantly between responders and non-responders. Duration of TT should be discussed with patients in shared decision-making when discussing palliative nivolumab.
Authors
- Michelle Bradbury
- Gregory R. Pond (ORCID: https://orcid.org/0000-0003-1033-0882)
- Adi Kartolo (ORCID: https://orcid.org/0000-0002-6303-5206)
- Brandon M. Meyers (ORCID: https://orcid.org/0000-0001-9673-6271)
- Adam Gabara
Institutions
- Juravinski Cancer Centre (CA)
- Hamilton Health Sciences (CA)
- McMaster University (CA)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1080/1750743x.2025.2518913
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05